Table 2.
Clinicopathologic Features of the GBM Cohort and Association with Clinical Outcome.
| Variable | Percentage of Cohort | Overall Survival* Median (95% CI) | Significance |
| Age at Diagnosis | 0.026† | ||
| <50 years | 23% | 15 months (5.7–24.3) | |
| 50–65 years | 61% | 17 months (12.0–22.0) | |
| >65 years | 16% | 12 months (5.6–18.4) | |
| Gender | 0.472 | ||
| Male | 77% | 17 months (11.4–22.6) | |
| Female | 23% | 13 months (6.9–19.1) | |
| ECOG score | 0.012† | ||
| 0 | 53% | 19 months (15.5–22.5) | |
| 1 | 42% | 13 months (12.2–13.7) | |
| 2 | 5% | 10 months | |
| Extent of Gross Resection | 0.295 | ||
| Partial | 9% | 22 months (10.2–33.8) | |
| Total | 91% | 15 months (12.3–17.7) | |
| MGMT Methylation | 0.432 | ||
| Unmethylated | 76% | 13 months (10.1–15.9) | |
| Methylated | 24% | 16 months (7.7–24.3) | |
| Status | |||
| Alive | 5% | ||
| Deceased | 95% |
*
Kaplan-Meier survival analysis results.
†
Statistically significant.